Next Article in Journal
Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside
Next Article in Special Issue
Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease
Previous Article in Journal
Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research
Previous Article in Special Issue
Efficacy of Artificial Tears Based on an Extract of Artemia salina Containing Dinucleotides in a Rabbit Dry Eye Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 2
10.3390/ijms23020664
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease

by
Takahiro Hirabayashi
1,
Junko Shibato
1,
Ai Kimura
1,
Michio Yamashita
2,
Fumiko Takenoya
2 and
Seiji Shioda
3,*
1
Clinical Medicine Research Laboratory, Shonan University of Medical Sciences, 16-48, Kamishinano, Totsuka-ku, Yokohama 244-0806, Japan
2
Department of Physiology and Molecular Sciences, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
3
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, 16-48, Kamishinano, Totsuka-ku, Yokohama 244-0806, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(2), 664; https://doi.org/10.3390/ijms23020664
Submission received: 27 November 2021 / Revised: 30 December 2021 / Accepted: 5 January 2022 / Published: 8 January 2022
(This article belongs to the Special Issue Dry Eye Disease–Focus on Drug Discovery and Development)
Browse Figure
Versions Notes

Abstract

Dry eye disease (DED) is caused by a reduction in the volume or quality of tears. The prevalence of DED is estimated to be 100 million in the developed world. As aging is a risk factor for DED, the prevalence of DED is expected to grow at a rapid pace in aging populations, thus creating an increased need for new therapies. This review summarizes DED medications currently in clinical use. Most current medications for DED focus on stimulating tear secretion, mucin secretion, or suppressing inflammation, rather than simply replenishing the ocular surface with moisture to improve symptoms. We recently reported that the neuropeptide PACAP (pituitary adenylate cyclase-activating polypeptide) induces tear secretion and suppresses corneal injury caused by a reduction in tears. Moreover, it has been reported that a PACAP in water and a 0.9% saline solution at +4 °C showed high stability and achieved 80–90% effectiveness after 2 weeks of treatment. These results reveal PACAP as a candidate DED medication. Further research on the clinical applications of PACAP in DED is necessary.
Keywords: dry eye disease; medication; drug discovery; PACAP; PAC1-R; tear secretion; peptide therapeutics dry eye disease; medication; drug discovery; PACAP; PAC1-R; tear secretion; peptide therapeutics

Share and Cite

MDPI and ACS Style

Hirabayashi, T.; Shibato, J.; Kimura, A.; Yamashita, M.; Takenoya, F.; Shioda, S. Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease. Int. J. Mol. Sci. 2022, 23, 664. https://doi.org/10.3390/ijms23020664

AMA Style

Hirabayashi T, Shibato J, Kimura A, Yamashita M, Takenoya F, Shioda S. Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease. International Journal of Molecular Sciences. 2022; 23(2):664. https://doi.org/10.3390/ijms23020664

Chicago/Turabian Style

Hirabayashi, Takahiro, Junko Shibato, Ai Kimura, Michio Yamashita, Fumiko Takenoya, and Seiji Shioda. 2022. "Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease" International Journal of Molecular Sciences 23, no. 2: 664. https://doi.org/10.3390/ijms23020664

APA Style

Hirabayashi, T., Shibato, J., Kimura, A., Yamashita, M., Takenoya, F., & Shioda, S. (2022). Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease. International Journal of Molecular Sciences, 23(2), 664. https://doi.org/10.3390/ijms23020664

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop